青蒿琥酯联合蒿甲醚治疗耐药恶性疟疾患者疗效观察

doi:10.3969/j.issn.1672-5069.2014.06.026

实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (6): 655-657.doi: 10.3969/j.issn.1672-5069.2014.06.026

青蒿琥酯联合蒿甲醚治疗耐药恶性疟疾患者疗效观察

段文斌, 严志刚, 段惠春, 周小平

730030 兰州市解放军第一医院感染病科（段文斌,严志刚,周小平）; 兰州石化总医院消化科（段惠春）

收稿日期:2013-12-25 出版日期:2014-12-31 发布日期:2016-04-11
通讯作者: 严志刚,E-mail:2192849972@qq.com
作者简介:段文斌, 男,48岁,大学本科,副主任医师。主要从事传染病的临床诊治工作。 E-mail：duan7521@sina.com

Efficacy of artesunate in treatment of patients with malaria

Duan Wenbin, Yan Zhigang, Duan Huichun

Department of Infectious Diseases,First Hospital,Military Command,Lanzhou 730030

Received:2013-12-25 Online:2014-12-31 Published:2016-04-11

摘要/Abstract

摘要： 目的探讨青蒿琥酯联合蒿甲醚治疗抗蒿甲醚的恶性疟疾患者的临床疗效。方法选择刚果耐药恶性疟疾患者60例,随机分为治疗组和对照组各30例,治疗组采用青蒿琥酯联合蒿甲醚治疗,对照组单纯应用青蒿琥酯。给药前和给药后每6 h涂厚、薄血片各1张,在第7 d、14 d和28 d采血检查疟原虫,观察原虫转阴时间及28 d复燃情况。结果在治疗7 d后,青蒿琥酯联合蒿甲醚治疗组和对照组治愈率分别为100%和96.7%（P>0.05）;治疗组和对照组退热时间分别为（24.25±2.78） h和（48.68±3.46,P<0.05）h,血疟原虫清除时间分别为（29.38±3.56） h和（59.65±4.29） h,P<0.01）;联合组在治疗后血细胞恢复正常的时间也明显短于对照组。结论青蒿琥酯联合蒿甲醚治疗恶性疟疗效优于青蒿琥酯单药治疗。

关键词: 恶性疟疾, 青蒿琥酯, 蒿甲醚, 疗效

Key words: [Key words] Malaria, Artesunate,Antimalarial resistance, Therapy

段文斌, 严志刚, 段惠春, 周小平. 青蒿琥酯联合蒿甲醚治疗耐药恶性疟疾患者疗效观察[J]. 实用肝脏病杂志, 2014, 17(6): 655-657.

Duan Wenbin, Yan Zhigang, Duan Huichun. Efficacy of artesunate in treatment of patients with malaria[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 655-657.

参考文献

[1] Kim JH,Choi AR,Kim YK,et al. Co-treatment with the anti-malarial drugs mefloquine and primaquine highly sensitizes drug-resistant cancer cells by increasing Pgp inhibition. Biochem Biophys Res Commun,2013,441（3）:655-660.
[2] Abolaji AO,Osedeme F,Olusemire O. Artesunate-amodiaquine combination therapy in the absence of malarial parasite infection induces oxidative damage in female rats. Cell Biochem Funct, 2013,12（3）:1002-1007.
[3] Chung MK,Yu WJ,Lee JS,et al. Embryotoxicity and toxicokinetics of the antimalarial artesunate in rats. Toxicol Res,2013,29（1）:27-34.
[4] Zakai HA,Khan W,Asma U. Prevalence of mutation and phenotypic expression associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum and Plasmodium vivax. Folia Parasitol （Praha）,2013,60（4）:372-376.
[5] Gosi P,Lanteri CA,Tyner SD,et al. Evaluation of parasite subpopulations and genetic diversity of the msp1,msp2 and glurp genes during and following artesunate monotherapy treatment of plasmodium falciparum malaria in western Cambodia. Malar J,2013,12（1）:403.
[6] Schleiferbock S,Scheurer C,Ihara M,et al. In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models. Drug Des Devel Ther,2013,15（7）:1377-1384.
[7] Le Manach C,Scheurer C,Sax S,et al. Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum. Malar J,2013,12（1）:424.
[8] Miranda AS,Brant F,Rocha NP,et al. Further evidence for an anti-inflammatory role of artesunate in experimental cerebral malaria. Malar J,2013,12（1）:388.
[9] Khattak AA,Venkatesan M,Jacob CG,et al.A comprehensive survey of polymorphisms conferring anti-malarial resistance in Plasmodium falciparum across Pakistan. Malar J,2013,12（1）:300. [10] Ojurongbe O,Lawal OA,Abiodun OO,et al.Efficacy of artemisinin combination therapy for the treatment of uncomplicated falciparum malaria in Nigerian children. J Infect Dev Ctries,2013,7（12）:975-982.
[11] Iribhogbe OI,Agbaje EO,Oreagba IA,et al. Oxidative stress and micronutrient therapy in malaria:an in vivo study in Plasmodium berghei infected mice. Pak J Biol Sci,2013,16（4）:160-167.
[12] Wu C,Liu J,Pan X,et al. Design,synthesis and evaluation of the antibacterial enhancement activities of amino dihydroartemisinin derivatives. Molecules,2013,18（6）:6866-6882.
[13] Olupot-Olupot P,Maitland K. Management of severe malaria: results from recent trials. Adv Exp Med Biol,2013,764:241-250. [14] Lopera-Mesa TM,Doumbia S,Chiang S,et al. Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria:effect of acquired immunity. J Infect Dis,2013,207（11）:1655-1663.
[15] Mishra N,Singh JP,Srivastava B,et al. Monitoring antimalarial drug resistance in India via sentinel sites:outcomes and risk factors for treatment failure,2009-2010. Bull World Health Organ,2012,90（12）:895-904.

青蒿琥酯联合蒿甲醚治疗耐药恶性疟疾患者疗效观察

Efficacy of artesunate in treatment of patients with malaria

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[2]	巴正武, 栗海龙, 杨慧. 能谱CT成像定量评估Budd-Chiari综合征患者TIPS术治疗前后肝功能状态临床价值研究*[J]. 实用肝脏病杂志, 2019, 22(5): 680-683.
[3]	张志成, 袁广庆, 莫灿均. 肝动脉栓塞术治疗三种类型肝血管瘤患者疗效及安全性分析*[J]. 实用肝脏病杂志, 2019, 22(5): 736-739.
[4]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[5]	严玲玲, 胡东辉, 黄艳芳. 腺苷蛋氨酸联合多烯磷酯酰胆碱治疗妊娠期肝内胆汁淤积症患者临床疗效初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 530-533.
[6]	王宝丹, 李萌, 高于. α-干扰素治疗慢性乙型肝炎儿童疗效及其影响疗效的因素分析[J]. 实用肝脏病杂志, 2019, 22(3): 345-348.
[7]	袁春晖, 李春雨, 李红丽, 赵红娜, 王文红, 孟庆旭, 张中学. 国产聚乙二醇化干扰素α治疗HBeAg阳性慢性乙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2019, 22(3): 353-356.
[8]	徐曼曼, 陈煜, 李爽. 特利加压素联合白蛋白输注治疗肝肾综合征患者疗效及尿NGAL和KIM-1对疗效的预测价值[J]. 实用肝脏病杂志, 2019, 22(3): 385-388.
[9]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.
[10]	赵鹏, 王磊. 聚乙二醇化干扰素-α对不同基因型慢性丙型肝炎患者治疗效果比较^*[J]. 实用肝脏病杂志, 2019, 22(1): 57-60.
[11]	闫焕杰, 张淑芹, 赵文静. 自体骨髓干细胞移植治疗慢加急性乙型肝炎肝衰竭患者疗效初步研究[J]. 实用肝脏病杂志, 2019, 22(1): 81-84.
[12]	曹艳平, 隋洪婷, 潘猛, 曲宝聚, 朴红心. 恩替卡韦联合聚乙二醇干扰素或胸腺素治疗代偿期乙型肝炎肝硬化2年疗效随访^*[J]. 实用肝脏病杂志, 2019, 22(1): 93-96.
[13]	王禅, 秦伟, 戴勇, 李晓峰, 张成强. 自体外周血干细胞移植治疗乙型肝炎肝硬化患者临床疗效及其对外周血T淋巴细胞亚群的影响[J]. 实用肝脏病杂志, 2019, 22(1): 97-100.
[14]	马履翔, 张雪松. 超声引导下经皮射频消融治疗小肝癌患者疗效及预后分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 125-128.
[15]	黄娇凤, 林苏, 王明芳, 黄映芳, 熊美连, 朱月永. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效及其对肝组织脂肪变的影响^*[J]. 实用肝脏病杂志, 2018, 21(6): 863-867.